Literature DB >> 17099070

Persistent negative symptoms in schizophrenia: an overview.

Robert W Buchanan1.   

Abstract

Persistent negative symptoms represent an alternative approach for assessing negative symptoms in the context of clinical trials. Persistent negative symptoms are designed to capture those symptoms that lead to functional impairment but are currently understudied and for which there are no currently available effective treatments. Persistent negative symptoms differ from the 2 most commonly used approaches: primary, enduring negative symptoms or deficit symptoms and negative symptoms broadly defined to include negative symptoms, regardless of their etiology or duration. In contrast to deficit symptoms, persistent negative symptoms may include secondary negative symptoms. However, in contrast to negative symptoms broadly defined, the secondary negative symptoms included in the assessment of persistent negative symptoms only include those that have failed to respond to usual treatments for secondary negative symptoms. In consequence, the presence of persistent negative symptoms identifies a patient population with clinically relevant symptomatology, which is larger than the one with the deficit syndrome but less heterogeneous than that captured through the use of a nonrestrictive definition of negative symptoms. This may facilitate the selection of subjects for inclusion into research and efforts to develop new pharmacological treatments and enhance our understanding of a relevant clinical problem. Ultimately, the investigation of the different entities characterized by negative symptoms, such as persistent negative symptoms, and the enhanced understanding of their biological and clinical characteristics may help to unravel the psychopathological and biological heterogeneity of schizophrenia.

Entities:  

Mesh:

Year:  2006        PMID: 17099070      PMCID: PMC2632326          DOI: 10.1093/schbul/sbl057

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  60 in total

1.  Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.

Authors:  A Kopelowicz; R Zarate; K Tripodis; V Gonzalez; J Mintz
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

2.  Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study.

Authors:  R Bottlender; U Wegner; J Wittmann; A Strauss; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

3.  Commentary: consensus statement on negative symptoms.

Authors:  John Kane
Journal:  Schizophr Bull       Date:  2005-10-12       Impact factor: 9.306

4.  An industry perspective on the NIMH consensus statement on negative symptoms.

Authors:  Larry Alphs
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

5.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

6.  Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy.

Authors:  Kathryn E Greenwood; Sabine Landau; Til Wykes
Journal:  Schizophr Bull       Date:  2005-07-27       Impact factor: 9.306

7.  Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.

Authors:  M E Kelley; D P van Kammen; D N Allen
Journal:  Am J Psychiatry       Date:  1999-03       Impact factor: 18.112

Review 8.  Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia.

Authors:  R W Buchanan; W T Carpenter
Journal:  J Nerv Ment Dis       Date:  1994-04       Impact factor: 2.254

Review 9.  Negative symptoms and cognitive deficits: what is the nature of their relationship?

Authors:  Philip D Harvey; Danny Koren; Abraham Reichenberg; Christopher R Bowie
Journal:  Schizophr Bull       Date:  2005-10-12       Impact factor: 9.306

10.  Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

Authors:  Peter Milev; Beng-Choon Ho; Stephan Arndt; Nancy C Andreasen
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

View more
  99 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

Authors:  Robert W Buchanan; Elaine Weiner; Deanna L Kelly; James M Gold; William R Keller; James A Waltz; Robert P McMahon; David A Gorelick
Journal:  Schizophr Bull       Date:  2014-11-02       Impact factor: 9.306

3.  Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.

Authors:  Anthony O Ahmed; Gregory P Strauss; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

4.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

5.  A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.

Authors:  Dawn I Velligan; David Roberts; Jim Mintz; Natalie Maples; Xueying Li; Elisa Medellin; Matt Brown
Journal:  Schizophr Res       Date:  2015-05-01       Impact factor: 4.939

Review 6.  Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.

Authors:  Joshua T Kantrowitz; Neal R Swerdlow; Walter Dunn; Sophia Vinogradov
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-02-22

7.  Cognitive behavior therapy for people with schizophrenia.

Authors:  Ann K Morrison
Journal:  Psychiatry (Edgmont)       Date:  2009-12

Review 8.  Antipsychotic drugs for first-episode schizophrenia: a comparative review.

Authors:  Kayvon Salimi; L Fredrik Jarskog; Jeffrey A Lieberman
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

9.  Religion's effect on mental health in schizophrenia: examining the roles of meaning-making and seeking social support.

Authors:  Naomi T Tabak; Amy Weisman de Mamani
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-07

10.  Deconstructing Negative Symptoms in Individuals at Clinical High-Risk for Psychosis: Evidence for Volitional and Diminished Emotionality Subgroups That Predict Clinical Presentation and Functional Outcome.

Authors:  Tina Gupta; Henry R Cowan; Gregory P Strauss; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.